Journal of Clinical Densitometry
Volume 11, Issue 4 , Pages 478-484 , October 2008

A Clinician's Perspective on the Use of Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis

  • E. Michael Lewiecki, MD, FACP, FACE

      Affiliations

    • Corresponding Author InformationAddress correspondence to: E. Michael Lewiecki, MD, FACP, FACE, New Mexico Clinical Research & Osteoporosis Center, 300 Oak St. NE, Albuquerque, NM 87106, USA.

Received 4 June 2008 ,Revised 15 July 2008 ,Accepted 16 July 2008.

References 

  1. WHO Study Group on Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva: World Health Organization; 1994;
  2. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312(7041):1254–1259
  3. Baim S, Binkley N, Bilezikian JP, et al. Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 position development conference. J Clin Densitom. 2008;11(1):75–91
  4. National Osteoporosis Foundation . Physician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation; 2003;
  5. Kanis JA, Johnell O, Oden A, et al. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int. 2001;12(12):989–995
  6. Black DM, Arden NK, Palermo L, et al. Prevalent vertebral deformities predict hip fractures and new vertebral fractures but not wrist fractures. J Bone Miner Res. 1999;14:821–828
  7. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA. 2001;285:320–323
  8. Rodan GA, Reszka AA. Bisphosphonate mechanism of action. Curr Mol Med. 2002;2(3):571–577
  9. US Department of Health and Human Services . Bone health and osteoporosis: a report of the surgeon general. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General; 2004;
  10. Gehlbach SH, Avrunin JS, Puleo E, Spaeth R. Fracture risk and antiresorptive medication use in older women in the USA. Osteoporos Int. 2007;18(6):805–810
  11. Bahl S, Coates PS, Greenspan SL. The management of osteoporosis following hip fracture: have we improved our care?. Osteoporos Int. 2003;14(11):884–888
  12. Morris CA, Carrino JA, Lang P, Solomon DH. Incidental vertebral fractures on chest radiographs. Recognition, documentation, and treatment. J Gen Intern Med. 2006;21(4):352–356
  13. Kothawala P, Badamgarav E, Ryu S, et al. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc. 2007;82(12):1493–1501
  14. Piette JD, Heisler M, Wagner TH. Cost-related medication underuse among chronically ill adults: the treatments people forgo, how often, and who is at risk. Am J Public Health. 2004;94(10):1782–1787
  15. Kardas P. Patient compliance with antibiotic treatment for respiratory tract infections. J Antimicrob Chemother. 2002;49(6):897–903
  16. Horwitz RI, Viscoli CM, Berkman L, et al. Treatment adherence and risk of death after a myocardial infarction. Lancet. 1990;336(8714):542–545
  17. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc. 2005;80(7):856–861
  18. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007;18(8):1023–1031
  19. Downey TW, Foltz SH, Boccuzzi SJ, et al. Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J. 2006;99(6):570–575
  20. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–497
  21. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81(8):1013–1022
  22. Lewiecki EM. Medications don't work if patients don't take them. South Med J. 2007;100(12):1190–1191
  23. Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther. 2006;28(2):236–242
  24. Cooper A, Drake J, Brankin E. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract. 2006;60(8):896–905
  25. Reginster JY, Rabenda V, Neuprez A. Adherence, patient preference and dosing frequency: understanding the relationship. Bone. 2006;38(4 Suppl 1):S2–S6
  26. Simon JA, Lewiecki EM, Smith ME, et al. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther. 2002;24(11):1871–1886
  27. Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum. 2006;54(6):1838–1846
  28. Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19(8):1241–1249
  29. Cauza E, Etemad M, Winkler F, et al. Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis. J Clin Pharm Ther. 2004;29(5):431–436
  30. Miller RG, Chretien KC, Meoni LA, et al. Comparison of intravenous pamidronate to standard therapy for osteoporosis: use in patients unable to take oral bisphosphonates. J Clin Rheumatol. 2005;11(1):2–7
  31. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41
  32. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809–1822
  33. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1479–1489
  34. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357(18):1799–1809
  35. National Osteoporosis Foundation . Clinician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation; 2008;
  36. MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008;148(3):197–213
  37. Thiebaud D, Sauty A, Burckhardt P, et al. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int. 1997;61(5):386–392

 Grant or research support: Merck, Eli Lilly, Novartis, sanofi–aventis, Amgen, Pfizer, Wyeth, Roche, GSK, Procter & Gamble; scientific advisory board or speakers' bureau: Merck, Eli Lilly, Novartis, sanofi–aventis, Amgen, Pfizer, Wyeth, Roche, GSK, Procter & Gamble, Upsher-Smith.

PII: S1094-6950(08)00211-4

doi: 10.1016/j.jocd.2008.07.003

Journal of Clinical Densitometry
Volume 11, Issue 4 , Pages 478-484 , October 2008

Article Tools

* Image Usage & Resolution